Abstract
Adenosines diverse physiological functions are mediated by four subtypes of receptors (A1, A2A, A2B and A3). The A1 adenosine receptor pharmacology and therapeutic application of ligands for this receptor are the subjects of this review. A1 receptors are present on the surface of cells in organs throughout the body. Actions mediated by A1 receptors include slowing of heart rate and AV nodal conduction, reduction of atrial contractility, attenuation of the stimulatory actions of catecholamines on beta-adrenergic receptors, reduction of lipolysis in adipose tissue, reduction of urine formation, and inhibition of neuronal activity. Although adenosine analogs with high efficacy, affinity, and selectivity for the A1 receptor are available, the ubiquitous distribution and wide range of physiological actions mediated by A1 receptors are obstacles to development of therapeutic agents that activate these receptors. However, it may be possible to exploit the high A1 “receptor reserve” for some actions of adenosine by use of weak (partial) agonists to target these actions while avoiding others for which receptor reserve is low. The presence of high receptor reserves for the anti-arrhythmic and anti-lipolytic actions of adenosine suggests that partial A1 agonists could be used as anti-arrhythmic and anti-lipolytic agents. In addition, allosteric enhancers of the binding of adenosine to A1 receptors could be used therapeutically to potentiate desirable effects of endogenous adenosine. Antagonists of the A1 receptor can increase urine formation, and because they do not decrease renal blood flow, are particularly useful to maintain glomerular filtration in patients having edema secondary to reduced cardiac function.
Keywords: adenosine, a1 receptor, anti-arrhythmic, anti-lipolytic, g protein-coupled receptor (gpcr)
Current Topics in Medicinal Chemistry
Title: Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands
Volume: 3 Issue: 4
Author(s): Arvinder K. Dhalla, John C. Shryock, Revati Shreeniwas and Luiz Belardinelli
Affiliation:
Keywords: adenosine, a1 receptor, anti-arrhythmic, anti-lipolytic, g protein-coupled receptor (gpcr)
Abstract: Adenosines diverse physiological functions are mediated by four subtypes of receptors (A1, A2A, A2B and A3). The A1 adenosine receptor pharmacology and therapeutic application of ligands for this receptor are the subjects of this review. A1 receptors are present on the surface of cells in organs throughout the body. Actions mediated by A1 receptors include slowing of heart rate and AV nodal conduction, reduction of atrial contractility, attenuation of the stimulatory actions of catecholamines on beta-adrenergic receptors, reduction of lipolysis in adipose tissue, reduction of urine formation, and inhibition of neuronal activity. Although adenosine analogs with high efficacy, affinity, and selectivity for the A1 receptor are available, the ubiquitous distribution and wide range of physiological actions mediated by A1 receptors are obstacles to development of therapeutic agents that activate these receptors. However, it may be possible to exploit the high A1 “receptor reserve” for some actions of adenosine by use of weak (partial) agonists to target these actions while avoiding others for which receptor reserve is low. The presence of high receptor reserves for the anti-arrhythmic and anti-lipolytic actions of adenosine suggests that partial A1 agonists could be used as anti-arrhythmic and anti-lipolytic agents. In addition, allosteric enhancers of the binding of adenosine to A1 receptors could be used therapeutically to potentiate desirable effects of endogenous adenosine. Antagonists of the A1 receptor can increase urine formation, and because they do not decrease renal blood flow, are particularly useful to maintain glomerular filtration in patients having edema secondary to reduced cardiac function.
Export Options
About this article
Cite this article as:
Dhalla K. Arvinder, Shryock C. John, Shreeniwas Revati and Belardinelli Luiz, Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands, Current Topics in Medicinal Chemistry 2003; 3 (4) . https://dx.doi.org/10.2174/1568026033392246
DOI https://dx.doi.org/10.2174/1568026033392246 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiotensin II Roles in Human Vascular Tone Control
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Chemo-drug Controlled-release Strategies of Nanocarrier in the Development of Cancer Therapeutics
Current Medicinal Chemistry Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Gender Related Issues in the Management of Heart Failure
Current Pharmaceutical Design Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Review of Recent Patents on Foldable Ventricular Assist Devices
Recent Patents on Biomedical Engineering (Discontinued) Computer-Assisted Methods in Chemical Toxicity Prediction
Mini-Reviews in Medicinal Chemistry NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry The Status of Disease Registries in the United States: Reflections
Applied Clinical Research, Clinical Trials and Regulatory Affairs Modified Fibrin Hydrogel Matrices: Both, 3D-Scaffolds and Local and Controlled Release Systems to Stimulate Angiogenesis
Current Pharmaceutical Design Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health
Current Medicinal Chemistry 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Central Arterial Aging and Angiotensin II Signaling
Current Hypertension Reviews Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions
Current Vascular Pharmacology